Survival-adjusted health-related quality of life (HRQL) among patients with metastatic breast cancer receiving paclitaxel plus bevacizumab versus paclitaxel alone: results from Eastern Cooperative Oncology Group Study 2100 (E2100)

✍ Scribed by David Cella; Molin Wang; Lynne Wagner; Kathy Miller

• Publisher: Springer US
• Year: 2011
• Tongue: English
• Weight: 241 KB
• Volume: 130
• Category: Article
• ISSN: 0167-6806
• DOI: 10.1007/s10549-011-1725-6